Animal models of Alzheimer's disease and drug development

Drug Discovery Today: Technologies

Volumn 10, Issue 3, 2013, Pages

  Laurijssens, Bart ^a   Aujard, Fabienne ^b   Rahman, Anisur ^b  

^a BEL Pharm Consulting   (France)

^b MNHN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; ALPHA TOCOPHEROL; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; CURCUMIN; DONEPEZIL; DOXYCYCLINE; GAMMA SECRETASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; IMMUNOGLOBULIN G; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; RIFAMPICIN; SIMVASTATIN;

ALZHEIMER DISEASE; ANIMAL MODEL; BLEEDING; CANCER RISK; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; EDEMA; GENETIC MODEL; HUMAN; NONHUMAN; PASSIVE IMMUNIZATION; PREDICTIVE VALIDITY; REVIEW; SIDE EFFECT; SKIN CANCER; TRANSGENICS; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 84879235411     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.04.001     Document Type: Review

References (71)

1. M.P. Mattson Pathways towards and away from Alzheimer's disease Nature 430 2004 631 639
2. J.A. Hardy, and G.A. Higgins Alzheimer's disease: the amyloid cascade hypothesis Science 256 1992 184 185
3. J. Schnabel Little proteins, big clues Nature 475 2011 S12 S14
4. D. Van Dam, and P.P. De Deyn Animal models in the drug discovery pipeline for Alzheimer's disease Br. J. Pharmacol. 164 2011 1285 1300
5. E. Johnstone Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis Mol. Brain Res. 10 1991 299 305
6. S. Languille The grey mouse lemur: a non human primate model for ageing studies Ageing Res. Rev. 11 2012 150 162
7. M. Dhenain Regional atrophy in the brain of lissencephalic mouse lemur primates: measurement by automatic histogram-based segmentation of MR images Magn. Reson. Med. 50 2003 984 992
8. N. Bons Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease? Genes Brain Behav. 5 2006 120 130
9. N. Mestre, and N. Bons Age-related cytological changes and neuronal loss in basal forebrain cholinergic neurons in Microcebus murinus (Lemurian, Primate) Neurodegeneration 2 1993 25 32
10. A. Kraska Age-associated cerebral atrophy in mouse lemur primates Neurobiol. Aging 32 2011 894 906
11. J.L. Picq Aging affects executive functions and memory in mouse lemur primates Exp. Gerontol. 42 2007 223 232
12. J-L. Picq Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments Neurobiol. Aging 33 2012 1096 1109
13. P. Giannakopoulos Quantitative analysis of tau protein-immunoreactive accumulations and β amyloid protein deposits in the cerebral cortex of the mouse lemur, Microcebus murinus Acta Neuropathol. 94 1997 131 139
14. J.J. Buccafusco Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders J. Alzheimer's Dis. 15 2008 709 720
15. J. De Magalhaes, and J. Costa A database of vertebrate longevity records and their relation to other life-history traits J. Evol. Biol. 22 2009 1770 1774
16. N. Braidy Recent rodent models for Alzheimer's disease: clinical implications and basic research J. Neural Transm. 119 2012 173 195
17. N.C. Inestrosa Human-like rodent amyloid-β-peptide determines Alzheimer pathology in aged wild-type Octodon degu Neurobiol. Aging 26 2005 1023 1028
18. D. Games Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein Nature 373 1995 523 527
19. W. Kalback APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques Biochemistry 41 2002 922 928
20. M. Goedert Tau protein, the paired helical filament and Alzheimer's disease J. Alzheimer's Dis. 9 2006 195 207
21. S. Oddo Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A [beta] and synaptic dysfunction Neuron 39 2003 409 421
22. H. Du Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease Nat. Med. 14 2008 1097 1105
23. Y.J. Lee Inflammation and Alzheimers disease Arch. Pharm. Res. 33 2010 1539 1556
24. T. Gomez-Isla Profound loss of layer II entorhinal cortex neurons distinguishes very mild Alzheimers disease from nondemented aging J. Neurosci. 16 1996 4450 4491
25. M. Driscoll, and B. Gerstbrein Dying for a cause: invertebrate genetics takes on human neurodegeneration Nat. Rev. Genet. 4 2003 181 194
26. K. Iijima, and K. Iijima-Ando Drosophila models of Alzheimer's amyloidosis: the challenge of dissecting the complex mechanisms of toxicity of amyloid-β 42 J. Alzheimers Dis. 15 2008 523 540
27. T.K. Sang, and G.R. Jackson Drosophila models of neurodegenerative disease NeuroRx 2 2005 438 446
28. C. Sinadinos Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons Neurobiol. Dis. 34 2009 389 395
29. S. Nakamura Progressive brain dysfunction following intracerebroventricular infusion of beta1-42-amyloid peptide Brain Res. 912 2001 128 136
30. W. Li A nonhuman primate model of Alzheimer's disease generated by intracranial injection of amyloid-beta42 and thiorphan Metab. Brain Dis. 25 2010 277 284
31. C. Duyckaerts Alzheimer disease models and human neuropathology: similarities and differences Acta Neuropathol. (Berl.) 115 2008 5 38
32. A. Fine Cholinergic ventral forebrain grafts into the neocortex improve passive avoidance memory in a rat model of Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 82 1985 5227 5230
33. U. Ebert, and W. Kirch Scopolamine model of dementia: electroencephalogram findings and cognitive performance Eur. J. Clin. Invest. 28 1998 944 949
34. A. Castane Selective lesions of the dorsomedial striatum impair serial spatial reversal learning in rats Behav. Brain Res. 210 2010 74 83
35. S. Frautschy Phenolic anti-inflammatory antioxidant reversal of A [beta]-induced cognitive deficits and neuropathology Neurobiol. Aging 22 2001 993 1005
36. P. Willner Validation criteria for animal models of human mental disorders: learned helplessness as a paradigm case Prog. Neuropsychopharmacol. Biol. Psychiatry 10 1986 677 690
37. D.F. Horrobin Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat. Rev. Drug Discov. 2 2003 151 154
38. H. Geerts Of mice and men: bridging the translational disconnect in CNS drug discovery CNS Drugs 23 2009 915 926
39. H.B. van der Worp Can animal models of disease reliably inform human studies? PLoS Med. 7 2010 e1000245
40. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat. Rev. Drug Discov. 2 2003 566 580
41. C.T. Dollery The challenge of complexity Clin. Pharmacol. Ther. 88 2010 13 15
42. A. Aderem Systems biology: its practice and challenges Cell 121 2005 511 513
43. E.C. Butcher Systems biology in drug discovery Nat. Biotechnol. 22 2004 1253 1259
44. H. Boxenbaum Pharmacokinetics: philosophy of modeling Drug Metab. Rev. 24 1992 89 120
45. T.F. Massoud Principles and philosophy of modeling in biomedical research FASEB J. 12 1998 275 285
46. J.M. Cedarbaum, and J.K. Wagg Predicting initial changes in brain volume with effective anti-amyloid agents: just ask alice Alzheimer's Demen. 2011 S46
47. P.W. Thompson, and A. Lockhart Monitoring the amyloid beta-peptide in vivo-caveat emptor Drug Discov. Today 14 2009 241 251
48. Simeoni M, et al. (2008) Modelling beta amyloid system: sensitivity analysis at steady state and in dynamic conditions. Population Analysis Group Europe (PAGE) Meeting, Marseille, France (Abstract 1396)
49. C.W. Cotman, and E. Head The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches J. Alzheimers Dis. 15 2008 685 707
50. E. Check Nerve inflammation halts trial for Alzheimer's drug Nature 415 2002 462
51. G.G. Fillenbaum Dementia and Alzheimer's disease in community-dwelling elders taking vitamin C and/or vitamin E Ann. Pharmacother. 39 2005 2009 2014
52. D. Schenk Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning Nat. Rev. Neurosci. 3 2002 824 828
53. D. Morgan Immunotherapy for Alzheimers disease J. Intern. Med. 269 2011 54 63
54. I. Hussain Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-β production in vivo J. Neurochem. 100 2007 802 809
55. M. Townsend Oral treatment with a γ-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease J. Pharmacol. Exp. Ther. 333 2010 110 119
56. M.Z. Kounnas Modulation of [gamma]-secretase reduces [beta]-amyloid deposition in a transgenic mouse model of Alzheimer's disease Neuron 67 2010 769 780
57. H. Dong Effects of donepezil on amyloid-[beta] and synapse density in the Tg2576 mouse model of Alzheimer's disease Brain Res. 1303 2009 169 178
58. J.K. Choi Anti-inflammatory treatment in AD mice protects against neuronal pathology Exp. Neurol. 223 2010 377 384
59. M. Boimel Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy J. Neuropathol. Exp. Neurol. 68 2009 314 325
60. Y. Nishida Depletion of vitamin E increases Amyloid β accumulation by decreasing its clearances from brain and blood in a mouse model of Alzheimer disease J. Biol. Chem. 284 2009 33400 33408
61. R. Costa Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer's disease J. Biol. Chem. 286 2011 41647 41655
62. T.E. Golde Targeting A [beta] and tau in Alzheimer's disease, an early interim report Exp. Neurol. 223 2010 252 266
63. A. Extance Alzheimer's failure raises questions about disease-modifying strategies Nat. Rev. Drug Discov. 9 2010 749 751
64. M. Sabbagh, and J. Cummings Progressive cholinergic decline in Alzheimer's disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology BMC Neurol. 11 2011 21
65. B.P. Imbimbo An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease Expert Opin. Invest. Drugs 18 2009 1147 1168
66. H. Feldman Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease Neurology 74 2010 956 964
67. M. Isaac Vitamin E for Alzheimer's disease and mild cognitive impairment Cochrane Database Syst Rev (Online) 2008 CD002854
68. M.B. Loeb A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease J. Am. Geriatr. Soc. 52 2004 381 387
69. T. Ahmed Curcuminoids enhance memory in an amyloid-infused rat model of Alzheimer's disease Neuroscience 169 2010 1296 1306
70. S. Hu GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals Neurobiol. Dis. 33 2009 193 206
71. A. Martinez Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment Int. J. Alzheimers Dis. 2011 2011 280502